Genomics and pharmacogenomics of lipid-lowering therapies

Docherty, K. F. and Padmanabhan, S. (2014) Genomics and pharmacogenomics of lipid-lowering therapies. In: Padmanabhan, S. (ed.) Handbook of Pharmacogenomics and Stratified Medicine. Academic Press: London, pp. 715-746. ISBN 9780123868831 (doi: 10.1016/B978-0-12-386882-4.00031-1)

Full text not currently available from Enlighten.

Publisher's URL:


Lipids are integral molecules in the body’s structure, and they are important substrates for energy metabolism. Abnormalities in plasma lipid levels (dyslipidemia), particularly cholesterol, have been associated with increased risk of cardiovascular disease. An individual’s plasma lipid profile is influenced by genetic, dietary, and environmental factors. Genetic factors include Mendelian monogenic disorders, which have become a focus for the pharmaceutical development of drugs that alter plasma lipid levels and in turn lower cardiovascular risk. more Common genetic variants affecting lipid levels have been identified, offering new avenues for risk estimation and “personalisation” of drug therapy. Response to lipid-lowering therapy and adverse effects vary among individuals. In this chapter we review current understanding of the genetic determinants of lipids and the pharmacogenomics of lipid-lowering drugs.

Item Type:Book Sections
Glasgow Author(s) Enlighten ID:Docherty, Dr Kieran and Padmanabhan, Professor Sandosh
Authors: Docherty, K. F., and Padmanabhan, S.
Subjects:R Medicine > RM Therapeutics. Pharmacology
College/School:College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
College of Medical Veterinary and Life Sciences > School of Medicine, Dentistry & Nursing
Publisher:Academic Press
Related URLs:

University Staff: Request a correction | Enlighten Editors: Update this record